WO2019132561A8 - 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 - Google Patents

카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 Download PDF

Info

Publication number
WO2019132561A8
WO2019132561A8 PCT/KR2018/016813 KR2018016813W WO2019132561A8 WO 2019132561 A8 WO2019132561 A8 WO 2019132561A8 KR 2018016813 W KR2018016813 W KR 2018016813W WO 2019132561 A8 WO2019132561 A8 WO 2019132561A8
Authority
WO
WIPO (PCT)
Prior art keywords
amino
kinase inhibitor
methyl piperidine
piperidine derivative
present
Prior art date
Application number
PCT/KR2018/016813
Other languages
English (en)
French (fr)
Other versions
WO2019132561A1 (ko
Inventor
김인우
김남윤
정승환
김보경
이준희
Original Assignee
주식회사 대웅제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11202004916YA priority Critical patent/SG11202004916YA/en
Priority to AU2018394996A priority patent/AU2018394996B2/en
Priority to CA3085160A priority patent/CA3085160C/en
Priority to MX2020006798A priority patent/MX2020006798A/es
Priority to CN201880083535.6A priority patent/CN111527088B/zh
Priority to MYPI2020002466A priority patent/MY196572A/en
Priority to RU2020124575A priority patent/RU2756505C1/ru
Application filed by 주식회사 대웅제약 filed Critical 주식회사 대웅제약
Priority to PE2020000794A priority patent/PE20210549A1/es
Priority to NZ765152A priority patent/NZ765152A/en
Priority to JP2020534937A priority patent/JP7024091B2/ja
Priority to US16/770,213 priority patent/US11407754B2/en
Priority to ES18897615T priority patent/ES2924225T3/es
Priority to TNP/2020/000081A priority patent/TN2020000081A1/en
Priority to EP18897615.3A priority patent/EP3733674B1/en
Priority to BR112020013237-3A priority patent/BR112020013237A2/pt
Publication of WO2019132561A1 publication Critical patent/WO2019132561A1/ko
Priority to DO2020000111A priority patent/DOP2020000111A/es
Priority to CONC2020/0007156A priority patent/CO2020007156A2/es
Publication of WO2019132561A8 publication Critical patent/WO2019132561A8/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염에 관한 것으로, 본 발명에 따른 화합물은 카이네이즈 저해 작용이 유익한 질환의 예방 또는 치료에 유용하게 사용할수 있다.
PCT/KR2018/016813 2017-12-28 2018-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 WO2019132561A1 (ko)

Priority Applications (17)

Application Number Priority Date Filing Date Title
TNP/2020/000081A TN2020000081A1 (en) 2017-12-28 2018-12-28 Amino-methyl piperidine derivative as kinase inhibitor
CA3085160A CA3085160C (en) 2017-12-28 2018-12-28 Amino-methylpiperidine derivatives as kinase inhibitor
MX2020006798A MX2020006798A (es) 2017-12-28 2018-12-28 Derivado de amino-metil piperidina como inhibidor de cinasa.
CN201880083535.6A CN111527088B (zh) 2017-12-28 2018-12-28 作为激酶抑制剂的氨基-甲基哌啶衍生物
MYPI2020002466A MY196572A (en) 2017-12-28 2018-12-28 Amino-Methyl Piperidine Derivative as Kinase Inhibitor
RU2020124575A RU2756505C1 (ru) 2017-12-28 2018-12-28 Производные аминометилпиперидина в качестве ингибитора киназы
JP2020534937A JP7024091B2 (ja) 2017-12-28 2018-12-28 キナーゼ阻害剤としてのアミノ－メチルピペリジン誘導体
PE2020000794A PE20210549A1 (es) 2017-12-28 2018-12-28 Derivado de amino-metil piperidina como inhibidor de quinasa
NZ765152A NZ765152A (en) 2017-12-28 2018-12-28 Amino-methyl piperidine derivative as kinase inhibitor
SG11202004916YA SG11202004916YA (en) 2017-12-28 2018-12-28 Amino-methyl piperidine derivative as kinase inhibitor
US16/770,213 US11407754B2 (en) 2017-12-28 2018-12-28 Substituted piperidines as kinase inhibitors
ES18897615T ES2924225T3 (es) 2017-12-28 2018-12-28 Derivado de amino-metilpiperidina como inhibidor de cinasa
AU2018394996A AU2018394996B2 (en) 2017-12-28 2018-12-28 Amino-methyl piperidine derivative as kinase inhibitor
EP18897615.3A EP3733674B1 (en) 2017-12-28 2018-12-28 Amino-methyl piperidine derivative as kinase inhibitor
BR112020013237-3A BR112020013237A2 (pt) 2017-12-28 2018-12-28 derivados de amino-metilpiperidina como iniciador quinase
DO2020000111A DOP2020000111A (es) 2017-12-28 2020-06-10 Derivado de amino-metil piperidina como inhibidor de quinasa
CONC2020/0007156A CO2020007156A2 (es) 2017-12-28 2020-06-11 Derivado de amino-metil piperidina como inhibidor de quinasa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170183062A KR102577242B1 (ko) 2017-12-28 2017-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR10-2017-0183062 2017-12-28

Publications (2)

Publication Number Publication Date
WO2019132561A1 WO2019132561A1 (ko) 2019-07-04
WO2019132561A8 true WO2019132561A8 (ko) 2020-06-11

Family

ID=67067897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/016813 WO2019132561A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체

Country Status (23)

Country Link
US (1) US11407754B2 (ko)
EP (1) EP3733674B1 (ko)
JP (1) JP7024091B2 (ko)
KR (1) KR102577242B1 (ko)
CN (1) CN111527088B (ko)
AU (1) AU2018394996B2 (ko)
BR (1) BR112020013237A2 (ko)
CA (1) CA3085160C (ko)
CL (1) CL2020001749A1 (ko)
CO (1) CO2020007156A2 (ko)
DO (1) DOP2020000111A (ko)
EC (1) ECSP20035588A (ko)
ES (1) ES2924225T3 (ko)
MA (1) MA51433A (ko)
MX (1) MX2020006798A (ko)
MY (1) MY196572A (ko)
NZ (1) NZ765152A (ko)
PE (1) PE20210549A1 (ko)
RU (1) RU2756505C1 (ko)
SA (1) SA520412334B1 (ko)
SG (1) SG11202004916YA (ko)
TN (1) TN2020000081A1 (ko)
WO (1) WO2019132561A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098716B2 (ja) 2017-08-01 2022-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
LT3733673T (lt) 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
KR102228668B1 (ko) * 2019-10-08 2021-03-17 (주)부흥산업사 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
BR112012033253A2 (pt) 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2013042006A1 (en) 2011-09-22 2013-03-28 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2014025486A1 (en) 2012-08-06 2014-02-13 Acea Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
PL2917138T3 (pl) 2012-11-08 2019-08-30 Compac Technologies Limited Nośnik artykułów dla urządzenia sortującego
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CN106065017B (zh) 2013-09-18 2018-06-01 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
SI3318565T1 (sl) 2013-12-05 2021-07-30 Pfizer Inc. Pirolo(2,3-D)pirimidinil, pirolo(2,3-B)pirazinil in pirolo(2,3-D)piridinil akrilamidi
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017106771A1 (en) 2015-12-16 2017-06-22 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
EP3950691A1 (en) 2016-06-30 2022-02-09 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
CN106432294B (zh) 2016-09-19 2018-01-30 淮北师范大学 发光配合物及其制备方法
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
LT3733673T (lt) 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius

Also Published As

Publication number Publication date
JP2021507923A (ja) 2021-02-25
DOP2020000111A (es) 2020-09-30
ES2924225T3 (es) 2022-10-05
KR20190080541A (ko) 2019-07-08
WO2019132561A1 (ko) 2019-07-04
EP3733674A4 (en) 2021-06-09
EP3733674B1 (en) 2022-06-29
AU2018394996A1 (en) 2020-06-25
PE20210549A1 (es) 2021-03-17
MA51433A (fr) 2021-04-07
BR112020013237A2 (pt) 2020-12-01
TN2020000081A1 (en) 2022-01-06
AU2018394996B2 (en) 2021-08-05
CL2020001749A1 (es) 2020-11-06
MY196572A (en) 2023-04-19
CN111527088A (zh) 2020-08-11
EP3733674A1 (en) 2020-11-04
MX2020006798A (es) 2020-09-03
SA520412334B1 (ar) 2022-11-03
NZ765152A (en) 2024-02-23
ECSP20035588A (es) 2020-07-31
RU2756505C1 (ru) 2021-10-01
CN111527088B (zh) 2022-12-30
SG11202004916YA (en) 2020-06-29
CA3085160A1 (en) 2019-07-04
KR102577242B1 (ko) 2023-09-11
CO2020007156A2 (es) 2020-06-19
JP7024091B2 (ja) 2022-02-22
US20210188854A1 (en) 2021-06-24
AU2018394996A2 (en) 2020-07-16
CA3085160C (en) 2021-12-07
US11407754B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12019500480A1 (en) Pyridine compound
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
MY193239A (en) Novel b-lactamase inhibitors
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12018500999A1 (en) Sodium channel blocker
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18897615

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3085160

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020534937

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018394996

Country of ref document: AU

Date of ref document: 20181228

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018897615

Country of ref document: EP

Effective date: 20200728

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020013237

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020013237

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200626